Clearmind Medicine Q3 2025 Earnings Report

Clearmind Medicine EPS Results

• Actual EPS: -$0.25
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Clearmind Medicine Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Clearmind Medicine Announcement Details

• Quarter: Q3 2025
• Date: 9/11/2025
• Time: After Market Closes
• Conference Call Date: N/A
• Conference Call Time: N/A

Clearmind Medicine (NASDAQ:CMND), Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel psychoplastogen-based therapeutics for neuropsychiatric and neurodegenerative disorders. The company leverages a proprietary chemistry platform to design small-molecule compounds that promote rapid and sustained neural plasticity without the hallucinogenic effects typically associated with psychedelic agents. By targeting fundamental mechanisms of synaptic growth and repair, Clearmind aims to address conditions ranging from mood and anxiety disorders to cognitive impairment in dementia.

Clearmind’s pipeline includes multiple preclinical and early clinical candidates. Among these is an iboga alkaloid analog designed to treat neuropathic pain and opioid use disorder, as well as a series of next-generation psychoplastogens for major depressive disorder and post-traumatic stress disorder. The company’s research programs also explore applications in mild traumatic brain injury and Alzheimer’s-type dementias, with the goal of delivering therapies that restore neural circuitry and improve cognitive function.

Headquartered in North America, Clearmind Medicine operates research facilities and partnerships across Canada and the United States. The company collaborates with academic institutions and contract research organizations to advance its drug candidates through toxicology studies and human trials. By combining proprietary medicinal chemistry with established preclinical models, Clearmind seeks to streamline development timelines and establish differentiated therapeutic profiles.

Clearmind’s leadership team comprises professionals with deep expertise in neuroscience, clinical development and regulatory affairs. The company’s board and scientific advisors include experts in psychopharmacology, neurology and drug development strategy, reflecting a commitment to rigorous science and commercial execution. As a Nasdaq-listed entity, Clearmind Medicine continues to expand its research collaborations and augment its pipeline in pursuit of new treatments for underserved neurological and psychiatric indications.